AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval as a 1L Treatment of Extensive-Stage Small Cell Lung Cancer
Shots:
- The approval is based on P-III CASPIAN trial assessing Imfinzi + SoC (etoposide & carboplatin/ cisplatin CT) or Imfinzi + CT + tremelimumab vs CT alone in 805 patients with ES-SCLC in 200 centers across 23 countries
- Results: the study met its 1EPs of OS in Jun’19- demonstrating a 27% reduction in risk of death with m-OS (13.0 vs 10.3mos.); ORR (68% vs 58%). An updated analysis demonstrated sustained efficacy after a median follow up 2+ yrs. with m-OS (12.9 vs 10.5mos.)- alive patients (22.2% vs 14.4%) @24mos.- safety & efficacy results were consistent with results in the overall global trial population
- Imfinzi is a mAb targeting PD-L1 & blocks interaction of PD-L1 with PD-1 & CD80
Ref: AstraZeneca | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com